Regenerex Pharma (RGPX) Cost of Revenue (2013 - 2023)

Regenerex Pharma (RGPX) has 7 years of Cost of Revenue data on file, last reported at $3000.0 in Q2 2023.

• Quarterly Cost of Revenue changed N/A year-over-year to $3000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4130.0 (changed N/A YoY) and the FY2020 annual result came in at $1712.0, changed N/A from the prior year.
• Cost of Revenue improved to $3000.0 in Q2 2023 per RGPX's latest filing, from $300.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $14296.0 in Q2 2019 and bottomed at $8.0 in Q2 2020.
• The 5-year median for Cost of Revenue is $488.0 (2020), against an average of $2069.2.
• The widest annual swing landed in 2020, when Cost of Revenue sank 99.94%; it then soared 30812.5% in 2021.
• Tracing RGPX's Cost of Revenue over 5 years: stood at $1570.0 in 2019, then tumbled by 76.82% to $364.0 in 2020, then jumped by 68.13% to $612.0 in 2021, then slumped by 50.98% to $300.0 in 2022, then surged by 900.0% to $3000.0 in 2023.
• Per Business Quant, the three latest RGPX Cost of Revenue figures stand at $3000.0 (Q2 2023), $300.0 (Q4 2022), and $612.0 (Q4 2021).

Peer Comparison